The State of the DNA Sequencing Market: Incredibly Boring Excitement
New sequencing platforms, falling prices, and a market that has barely moved. A look at competition and market share through 2025.
Read articleBlog
Genomics insights
Market analysis and commentary by Shawn Baker.
Element Joins the High-Throughput Market with the VITARI Platform
Element’s VITARI promises $100 genomes on a benchtop sequencer. A look at pricing, throughput, and its place alongside NovaSeq X and Axelios.
Read article
Roche’s Fantasy Sequencer Slowly Turning Into a Fantastic Reality
A closer look at Roche’s sequencing by expansion platform: speed, throughput, accuracy, early access data, and its potential place in the market.
Read article
Roche has entered the conversation…
Ahead of Roche’s SBX unveiling, a look at the technology, expected performance, and open questions about its arrival in the sequencing market.
Read articlePacBio’s Vega System – The New Small Thing in Long Reads
PacBio’s desktop Vega lowers the cost of entry to HiFi sequencing. What will its price and throughput mean for customers and the long read market?
Read articlePacBio’s new SPRQ chemistry brings down the LR human genome to $500. Is it enough to move the needle (faster)?
PacBio’s SPRQ chemistry cuts the HiFi human genome cost to $500. Will lower prices and improved chemistry accelerate the shift to long reads?
Read article2023 Sequencing Market Share - The Tide is Turning… Very Slowly
New competitors and long reads are gaining ground, but slowly. Comparing sequencing market share and revenue in 2022 and 2023.
Read article2022 Sequencing Market Share - Same As It Ever Was (For Now)
A revenue-based estimate of sequencing market share in 2022, with company-by-company figures and the methodology behind them.
Read articleMGI Breaks the $100 genome barrier, barely
MGI’s DNBSEQ-T20 promises $99 genomes at enormous scale. A closer look at reagent rental, sample commitments, and competing sequencing costs.
Read articleElement Beats Illumina to the $200 Genome
Element’s $200 genome arrives ahead of Illumina’s. A closer look at the instrument commitment, annual sample volumes, and cost trade-offs.
Read article2022 in Review
A review of the sequencing companies, platform launches, and competitive shifts of 2022—and the questions facing the industry in 2023.
Read articleThe Long and the Short of it: PacBio’s ASHG Announcements
PacBio announces Revio and Onso at ASHG: a look at long read throughput, short read accuracy, pricing, and the competitive landscape.
Read articleIllumina's 2022 Product Roadmap
NovaSeq X, XLEAP-SBS, and the NextSeq roadmap: a look at Illumina’s announcements, pricing, and the opportunities they leave for competitors.
Read articleFTC Suing to Block Illumina’s Acquisition of GRAIL
Six observations on the FTC’s challenge to Illumina’s proposed GRAIL acquisition and the implications for liquid biopsy competitors.
Read articleGet in touch
Genomics expertise.
Clear direction.
Shawn Baker · SanDiegOmics